News from mind medicine (mindmed) inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 19, 2022, 07:30 ET MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

May 16, 2022, 07:30 ET MindMed Reports First Quarter 2022 Financial Results and Business Highlights

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to...

May 12, 2022, 07:30 ET MindMed to Host Key Opinion Leader Webinar on Substance Use Disorders and Withdrawal Management

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

May 11, 2022, 07:30 ET MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders

- Results from the placebo-controlled investigator-initiated trial, conducted at the University Hospital Basel (UHB), demonstrate the significant,...

Apr 14, 2022, 07:30 ET MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

Apr 05, 2022, 07:30 ET MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health...

Mar 28, 2022, 07:30 ET MindMed Reports Full Year 2021 Financial Results and Business Highlights

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

Mar 25, 2022, 17:30 ET MindMed Announces Transition of CFO

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

Mar 21, 2022, 07:30 ET MindMed to Host Earnings Call to Discuss Full-Year 2021 Financial Results and Provide Business Update

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health...

Mar 09, 2022, 07:30 ET MindMed to Participate in March Investor Conferences

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical-stage biopharmaceutical company developing novel products to treat brain health...

Mar 02, 2022, 07:30 ET MindMed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for...

Feb 23, 2022, 07:30 ET MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing...

Jan 25, 2022, 07:30 ET FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing...

Jan 18, 2022, 07:30 ET MindMed Enrolls First Participant in a Study of its Session Monitoring System

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing...

Jan 07, 2022, 16:40 ET Stephen Hurst Resigns from MindMed Board of Directors

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-derived...

Jan 04, 2022, 07:30 ET MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-derived...

Dec 30, 2021, 07:30 ET MindMed to Participate at the LifeSci Partners 11th Annual Corporate Access Event

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired...

Dec 29, 2021, 07:30 ET MindMed Announces Transitions to Management Team

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired...

Dec 21, 2021, 07:30 ET MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired...

Dec 17, 2021, 07:30 ET MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired...

Dec 14, 2021, 07:30 ET MindMed Appoints Robert Barrow as Chief Executive Officer and Director

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired...

Dec 09, 2021, 07:30 ET MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired...

Dec 02, 2021, 07:30 ET MindMed to Participate at the Benzinga Global Small Cap Conference

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired...

Dec 01, 2021, 07:30 ET MindMed to Present at H.C. Wainwright 2nd Annual Psychedelics Conference

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired...

Nov 30, 2021, 07:30 ET MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ); (the "Company"), a leading biotech company developing psychedelic-inspired...